- For Print
- May 1, 2025
Listed Company Name: 亚洲彩票官网., Ltd.
Representative: Haruo Naito
Representative Corporate Officer and CEO
Securities Code: 4523
Stock Exchange Listings: Prime Market of the Tokyo Stock Exchange
Inquiries: Teruyuki Masaka
Vice President, Corporate Communications
Phone +81-3-3817-5120
亚洲彩票官网., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “亚洲彩票官网”) announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta protofibril antibody “LEQEMBI®” (generic name: lecanemab) was JPY 14.7 billion for the fourth quarter of fiscal year 2024 (January 1, 2025 – March 31, 2025) and JPY 44.3 billion for the full fiscal year 2024 (April 1, 2024 – March 31, 2025).
This information is being disclosed in conjunction with today's announcement of the financial results for the first quarter of 2025 by Biogen Inc. (Headquarters: Cambridge, Massachusetts). 亚洲彩票官网’s financial results for the fiscal year 2024, including details of LEQEMBI’s revenue, will be disclosed in 亚洲彩票官网's financial disclosure scheduled for May 15, 2025.
亚洲彩票官网 serves as the lead of lecanemab development and regulatory submissions globally with both 亚洲彩票官网 and Biogen Inc. co-commercializing and co-promoting the product and 亚洲彩票官网 having final decision-making authority.